Raf kinases are a family of three serine/threonine-specific protein kinases that are related to retroviral oncogenes.Rapidly Accelerated Fibrosarcoma is referred to as RAF. The RAS-RAF-MEK-ERK signal transduction cascade, also known as the mitogen-activated protein kinase (MAPK) cascade, involves Raf kinases. Interaction with RAS-GTPases is necessary for RAF kinase activation. A-RAF, B-RAF, and C-RAF (Raf-1) are the three members of the RAF kinase family. The B-Raf protein is involved in transmitting signals within cells that control cell growth.It was demonstrated that it was flawed (mutated) in a few human cancers. The RAF1 gene in humans encodes the enzyme C-RAF, also known as Raf-1. The c-Raf protein is a MAP kinase kinase (MAP3K) that works after the Ras subfamily of membrane-associated GTPases. It is a component of the ERK1/2 pathway. C-Raf is a member of the TKL (Tyrosine-kinase-like) group of protein kinases and belongs to the Raf kinase family of serine/threonine-specific protein kinases.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V2920 | RAF709 | 1628838-42-5 | RAF709 is a novel and potent inhibitor of the Raf kinase B/C isoforms (compound example 131 from patent WO2014151616A1) developed through a hypothesis-driven approach focusing on drug-like properties. |
|
V74148 | SB-682330A | 502498-66-0 | SB-682330A is a Raf kinase inhibitor. |
|
V115809 | SB-699393 | 502638-39-3 | SB-699393 (compound 17) is a BRAF inhibitor (Kd = 7.2 nM) that can cross the blood-brain barrier. |
|
V1008 | SB590885 | 405554-55-4 | SB590885 (SB 590885; SB-590885) is a novel and potent B-Raf inhibitor with potential antineoplastic activity. |
|
V98069 | SJ-C1044 | 2121503-76-0 | SJ-C1044 is an oral pan-RAF inhibitor with immunomodulatory and anti-tumor effects. |
|
V1012 | TAK-632 | 1228591-30-7 | TAK-632 (TAK 632; TAK632) is a novel and potent pan-Raf inhibitor with potential antineoplastic activity. |
|
V87106 | Tat-braftide | Tat-braftide is a peptide inhibitor that blocks the dimerization of BRAF, thereby inhibiting its kinase activity. | |
|
V74136 | TBAP-001 | 1777832-90-2 | TBAP-001 (Synthesis 13) information comes from patent WO2015075483A1. |
|
V2669 | Tovorafenib (MLN2480; TAK-580) | 1096708-71-2 | Tovorafenib (MLN2480; BIIB-024;BSK1369; DAY-101;TAK-580;AMG-2112819)is an orally bioactive, potent and selective pan-Raf kinase inhibitor with potential anticancer activity. |
|
V74134 | Uplarafenib (B-Raf IN 10) | 1425485-87-5 | Uplarafenib (B-Raf IN 10) is a BRAF inhibitor (antagonist) with IC50 in the range of 50-100 nM. |
|
V81731 | Vem-L-Cy5 | Vem-L-Cy5 (compound 3) is a Vemurafenib-based BRAF inhibitor modified with the near-infrared fluorophore cyanine-5 (Cy5). | |
|
V13500 | Exarafenib | 2639957-39-2 | Exarafenib (RAF/KIN_2787) is an orally bioactive pan-RAF inhibitor. |
|
V1014 | Encorafenib (LGX818) | 1269440-17-6 | Encorafenib (formerly LGX818; LGX-818; trade name Braftovi), an approved anticancer drug, is a highly potent, and orally bioavailable B-RAFV600E inhibitor with potential antineoplastic activity. |
|
V1003 | Sorafenib Tosylate (Bay 43-9006; Nexavar) | 475207-59-1 | Sorafenib Tosylate (BAY439006; BAY-439006; BAY549085; BAY-549085; Nexavar; SFN), the tosylate salt of Sorafenib which is an approved anticancer medication, is a potent multi-kinase inhibitor of Raf-1, B-Raf and VEGFR-2 with potential antineoplastic activity. |
|
V1010 | Sorafenib (Bay 43-9006) | 284461-73-0 | Sorafenib (BAY549085; BAY-549085; BAY439006; BAY-439006; Nexavar; SFN), an approved anticancer drug, is a potent and orally bioavailable multikinase inhibitor with potential anticancer activity. |
|
V1001 | Vemurafenib (PLX4032; RG7204; RO5185426) | 918504-65-1 | Vemurafenib (formerly PLX-4032; RG7204; RG-7204;RO5185426; RO-5185426;PLX4032; trade name: Zelboraf) is a potent and selective inhibitor of B-RafV600E mutated form with potential antineoplastic activity. |
|
V8230 | Belvarafenib (GDC-5573, HM-95573, RG-6185) | 1446113-23-0 | Belvarafenib (GDC-5573, HM95573, RG6185) is a novel, potent and selective inhibitor of the RAF (Rapidly Accelerated Fibrosarcoma) family kinases with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively. |
|
V1004 | Dabrafenib (GSK2118436) | 1195765-45-7 | Dabrafenib (formerly known as GSK2118436; GSK-2118436; GSK-2118436A; GSK-2118436B. Trade name: Tafinlar) is a novel, specific, orally bioavailable inhibitor of BRAF V600 mutants with potential anticancer activity. |
|
V3634 | Dabrafenib mesylate | 1195768-06-9 | Dabrafenib mesylate (formerly GSK-2118436 mesylate; Tafinlar), themesylate salt of dabrafenib, is an orally bioavailable BRAF V600 inhibitor that has been approved in 2013 by FDA to treat melanoma. |
|
V5307 | Naporafenib (LXH-254) | 1800398-38-2 | Naporafenib (LXH254;LXH-254),extracted from patent WO2018051306A1, compound A, is a novel, potent and orally bioavailable C-RAF inhibitor with anticancer activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
